糖尿病患者中4个月利福喷丁方案治疗结核病的疗效与安全性
研究纳入2516例随机分组受试者,其中181例(7.2%)患糖尿病。在166例糖尿病患者微生物学合格分析组中,对照组不利结局为26.3%(15/57),利福喷丁/莫西沙星组为13.8%(8/58),利福喷丁组为29.4%(15/51);对照组与利福喷丁/莫西沙星组差值为-12.5%(95%CI -27.0%至1.9%),与利福喷丁组差值为3.1%(95%CI -13.8%至20.0%)。利福喷丁/莫西沙星组与对照组安全性相似,作者认为该方案可用于结核病合并糖尿病患者。
要点
- 糖尿病患者占全部随机受试者的7.2%(181/2516)。
- 糖尿病患者中利福喷丁/莫西沙星组不利结局最少(13.8%)。
- 利福喷丁/莫西沙星组与对照组安全性相似。
核心结论
- 在结核病合并糖尿病患者中,利福喷丁/莫西沙星组不利结局最少且安全。
- 作者认为利福喷丁/莫西沙星方案可用于结核病合并糖尿病患者。
研究设计与样本
- 研究为对既往随机试验中糖尿病受试者的探索性分析,共2516例随机分组受试者,其中181例(7.2%)患糖尿病。
- 微生物学合格分析组中糖尿病患者共166例,对照组57例、利福喷丁/莫西沙星组58例、利福喷丁组51例。
主要发现
- 微生物学合格分析组中,对照组不利结局为26.3%(15/57),利福喷丁/莫西沙星组为13.8%(8/58),利福喷丁组为29.4%(15/51)。
- 对照组与利福喷丁/莫西沙星组不利结局比例差值为-12.5%(95%CI -27.0%至1.9%)。
- 对照组与利福喷丁组不利结局比例差值为3.1%(95%CI -13.8%至20.0%)。
- 利福喷丁/莫西沙星组与对照组安全性结局相似。
临床怎么用
- 作者认为利福喷丁/莫西沙星方案可用于结核病合并糖尿病患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We explored results among study participants with diabetes. Among 2,516 randomized participants, 181 (7.2%) had diabetes. Of 166 participants with diabetes in the microbiologically eligible analysis group, 26.3% (15/57) had unfavorable outcomes in the control regimen, 13.8% (8/58) in the rifapentine/moxifloxacin regimen, and 29.4% (15/51) in the rifapentine regimen. The difference in proportion of unfavorable outcomes between the control and rifapentine/moxifloxacin arms in the microbiologically eligible analysis group was -12.5% (95% CI -27.0% to 1.9%); the difference between the control and rifapentine arms was 3.1% (95% CI -13.8% to 20.0%). Safety outcomes were similar in the rifapentine/moxifloxacin regimen and control arms. Among participants with TB and diabetes, the rifapentine/moxifloxacin arm had fewest unfavorable outcomes and was safe. Our findings indicate that the rifapentine/moxifloxacin regimen can be used in persons with TB and diabetes.
引用
- Kurbatova EV, Whitworth WC, Peddareddy LP, et al. Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025. PMID: 40023788. doi:10.3201/eid3103.241634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。